PMID- 15038105
OWN - NLM
STAT- MEDLINE
DCOM- 20040408
LR  - 20201208
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 62
IP  - 3
DP  - 2004 Mar
TI  - [The role of mucoprotective drugs in gastric ulcer treatment: with specifical 
      reference to their effects on gastritis mucosa].
PG  - 566-70
AB  - A study group supported by Ministry of Health, Labor and Welfare recently 
      reported the Japanese guideline for gastric ulcer treatment which suggests that 
      gastric ulcer can be cured by either H. pylori eradication or acid suppression 
      therapy by proton pump inhibitors(PPI) and H2-receptor antagonists(H2RA). It also 
      suggests that all mucoprotective drugs except sucrafate, misoprostol and 
      enprostil can't be recommended for gastric ulcer treatment. However, some 
      mucoprotective drugs have been shown to possess anti-inflammatory action, leading 
      to the inhibition of leucocyte infiltration in H. pylori gastritis, while 
      long-term usage of PPI and H2RA might worsen gastritis. Thus, mucoprotective 
      drugs should be investigated in terms of long-term effects on H. pylori-gastritis 
      rather than the effects on gastric ulceration.
FAU - Sakamoto, Choitsu
AU  - Sakamoto C
AD  - Third Department of Internal Medicine, Nippon Medical School.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
MH  - Gastric Mucosa/*drug effects
MH  - Helicobacter Infections/drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Stomach Ulcer/*drug therapy
RF  - 11
EDAT- 2004/03/25 05:00
MHDA- 2004/04/09 05:00
CRDT- 2004/03/25 05:00
PHST- 2004/03/25 05:00 [pubmed]
PHST- 2004/04/09 05:00 [medline]
PHST- 2004/03/25 05:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2004 Mar;62(3):566-70.